Humana (HUM) came out with quarterly earnings of $11.58 per share, beating the Zacks Consensus Estimate of $9.98 per share. This compares to earnings of $7.23 per share a year ago.
HUM's first-quarter results are likely to benefit from higher Medicare stand-alone PDP revenues.
Beyond analysts' top -and-bottom-line estimates for Humana (HUM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Shares of health insurance operators surged Tuesday after the government said it would pay a higher rate to Medicare insurers than previously estimated.
Shares of US healthcare insurers moved higher following the announcement of a significant increase in 2026 Medicare insurer payment rates under the Trump administration. The government announced a 5.06% average increase in payments to private insurers managing Medicare Advantage plans, more than double the 2.23% initially proposed in January under the Biden administration.
Aquiles Larrea turns to three companies he believes will withstand the storm of tariffs and swelling volatility. He talks about the upside potential he sees in Consolidated Edison (ED), Humana (HUM), and American Water Works (AWK).
HUM benefits from a cost-effective health plan suite, continued expansion endeavors and a strong 2025 business outlook.
The easy accessibility for patients will give HUM a competitive edge over other senior-focused healthcare providers.
HUM's CenterWell and Conviva partner with Icon Health, improving musculoskeletal care access for seniors.
The medical sector giant was one of the first carriers to sound the alarm of rising inpatient utilization costs, notably with its Medicare Advantage (MA) plan members in Q4 2023.